On Tuesday, Delhi's All India Institute of Medical Sciences (AIIMS) began clinical trials of Bharat Biotech's Covaxin, India's first indigenously developed COVID-19 vaccine, on children aged 2-6 years.
On Tuesday, Delhi's All India Institute of Medical Sciences (AIIMS) began clinical trials of Bharat Biotech's Covaxin, India's first indigenously developed COVID-19 vaccine, on children aged 2-6 years.